Stopping a GLP-1 Before Surgery: The Anesthesia Guidance

GLP-1 receptor agonists like semaglutide and tirzepatide work partly by slowing down how fast food leaves the stomach. That’s useful for appetite control, but it becomes a different kind of problem when someone needs general anesthesia, where an empty stomach is the whole point of fasting rules in the first place. Anesthesiology groups have spent the last couple of years catching up to this, and the guidance is still being refined.

Why gastric emptying matters under anesthesia

Standard preoperative fasting — commonly “nothing to eat for 8 hours, clear liquids allowed up to 2 hours before” — assumes a stomach that empties at a normal rate. The whole strategy exists to reduce the risk of regurgitation and aspiration (stomach contents entering the lungs) once a patient is sedated and their airway reflexes are blunted.

GLP-1 drugs interfere with that assumption. Because they slow gastric motility, some patients on these medications still have retained food or liquid in the stomach after a fast that would normally be considered adequate. Case reports and small case series have described patients on semaglutide or similar drugs found to have significant residual gastric contents on endoscopy or during induction of anesthesia despite following standard fasting instructions. That’s the specific concern driving new guidance — not a claim that GLP-1s cause dangerous surgery outcomes broadly, but that the usual fasting rule of thumb may not reliably predict an empty stomach in this population.

It’s worth noting this risk isn’t unique to weight-management use. It applies to anyone on a GLP-1, including people taking it for type 2 diabetes at lower doses, though the effect on gastric emptying may be more pronounced earlier in treatment or after a recent dose increase.

What the ASA guidance actually says

The American Society of Anesthesiologists (ASA) issued consensus-based guidance addressing this gap, since there wasn’t strong trial evidence to draw on and gastroenterology and anesthesiology societies didn’t fully agree on an approach. The broad strokes, aimed at elective procedures requiring sedation or general anesthesia, are:

• For patients on a once-weekly GLP-1 (like semaglutide or tirzepatide), consider holding the dose the week of surgery — so the last dose falls roughly a week before the procedure.
• For patients on a daily GLP-1 (like liraglutide), consider skipping the dose on the day of surgery.
• If a patient has GI symptoms suggesting delayed emptying (nausea, vomiting, reflux, feeling full quickly) on the day of the procedure, treat them as a full-stomach precaution regardless of fasting time — this can mean postponing an elective case or using anesthesia techniques (like rapid-sequence induction) that reduce aspiration risk.
• Point-of-care gastric ultrasound has been proposed as a way to check for retained contents when there’s uncertainty, though it isn’t universally available or standardized.

This is guidance, not a hard rule, and the ASA has been explicit that it’s a starting framework meant to be refined as more data comes in — not a settled protocol backed by randomized trials. Individual hospitals and anesthesia groups have adapted it differently, and some clinicians weigh the tradeoffs (surgical risk from an unstable stomach versus the downside of interrupting a chronic medication) differently case by case.

The honest summary: holding a GLP-1 before surgery is a reasonable precaution anesthesiologists increasingly take, but it’s a judgment call built on limited evidence, not a proven-safe protocol — which is exactly why your surgical team needs to know you’re on one.

What this means if you’re on a GLP-1 and have surgery scheduled

There are a few practical takeaways, none of which substitute for talking to your own care team:

• Disclose it early. Tell whoever is scheduling your procedure, your surgeon, and your anesthesiologist that you’re taking a GLP-1, including the specific drug, dose, and your last dose date. This should happen at the preoperative visit, not casually mentioned in the pre-op holding area.
• Don’t stop or adjust dosing on your own. If you have diabetes, holding a GLP-1 can affect blood sugar control, and the decision about how and when to pause it should involve whoever manages that medication, not just the surgical team.
• Expect variation between practices. Some anesthesia groups follow the ASA framework closely; others have their own institutional protocols, or may ask additional questions about recent GI symptoms. Neither approach is objectively “more correct” given the current evidence — it reflects a field still working out best practice.
• Report symptoms on the day of surgery. Nausea, unusual fullness, or reflux the morning of a procedure is relevant information for your anesthesia team, even if it seems minor.

The takeaway

GLP-1 drugs slow the stomach down enough that standard fasting rules don’t always guarantee an empty stomach before anesthesia, and aspiration is a serious enough risk that anesthesiologists have moved to a precautionary approach: hold the weekly dose the week before elective surgery, skip the daily dose the day of, and treat GI symptoms as a red flag regardless of fasting time. The evidence behind this is still thin — mostly case reports and expert consensus rather than controlled trials — so guidance will likely keep shifting. What doesn’t change is the need to tell your surgical and anesthesia team you’re on one of these medications well before the day of the procedure, and to let them, not general internet advice, make the final call on timing.

Sources

• American Society of Anesthesiologists. Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists
• American Gastroenterological Association. AGA Guidance on Perioperative Management of GLP-1 Receptor Agonists
• U.S. Food and Drug Administration. Ozempic (semaglutide) prescribing information — gastrointestinal adverse effects